tiprankstipranks
Moonlake Immunotherapeutics (MLTX)
NASDAQ:MLTX
US Market
MLTX
MoonLake Immunotherapeutics
RESEARCH TOOLSreports
Want to see MLTX full AI Analyst Report?

MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

668 Followers
See the Price Targets and Ratings of:

MLTX Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
8 Buy
1 Hold
1 Sell
Based on 10 analysts giving stock ratings to
MoonLake
Immunotherapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MLTX Stock 12 Month Forecast

Average Price Target

$34.44
▲(81.10% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for MoonLake Immunotherapeutics in the last 3 months. The average price target is $34.44 with a high forecast of $70.00 and a low forecast of $12.00. The average price target represents a 81.10% change from the last price of $19.02.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","71":"$71","22.25":"$22.3","38.5":"$38.5","54.75":"$54.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.44444444444444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,22.25,38.5,54.75,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.44,22.40615384615385,26.372307692307693,30.33846153846154,34.30461538461539,38.27076923076923,42.23692307692308,46.20307692307692,50.16923076923077,54.13538461538462,58.10153846153847,62.06769230769231,66.03384615384616,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.44,19.671111111111113,20.90222222222222,22.133333333333333,23.364444444444445,24.595555555555556,25.826666666666668,27.057777777777776,28.288888888888888,29.52,30.751111111111108,31.98222222222222,33.21333333333333,{"y":34.44444444444444,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.44,17.944615384615386,17.44923076923077,16.953846153846154,16.45846153846154,15.963076923076924,15.467692307692309,14.972307692307693,14.476923076923077,13.981538461538463,13.486153846153847,12.990769230769232,12.495384615384616,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.52,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.73,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.82,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.13,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.44,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$34.44Lowest Price Target$12.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MLTX
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$45
Buy
136.59%
Upside
Reiterated
07/20/26
Analyst Maintains Buy on MoonLake, Reiterates $45 Price Target on Strong Financing and Sonelokimab Commercial Potential
Guggenheim Analyst forecast on MLTX
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$40
Buy
110.30%
Upside
Reiterated
06/22/26
Guggenheim Remains a Buy on MoonLake Immunotherapeutics (MLTX)
BTIG Analyst forecast on MLTX
Julian Harrison
BTIG
BTIG
$30
Buy
57.73%
Upside
Reiterated
06/22/26
Buy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained
LifeSci Capital Analyst forecast on MLTX
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$33
Buy
73.50%
Upside
Reiterated
06/22/26
MoonLake Reiterated at Buy as Sonelokimab Data Underscore HS Potential; $33 Price Target Maintained
Needham Analyst forecast on MLTX
Serge Belanger
Needham
Needham
$30
Buy
57.73%
Upside
Reiterated
06/22/26
Buy Rating Reiterated on SLK’s Strong Phase 3 HS Data and BLA Path; $30 Price Target Maintained
Clear Street Analyst forecast on MLTX
Kaveri Pohlman
Clear Street
Clear Street
$70
Buy
268.03%
Upside
Reiterated
06/22/26
MoonLake's SLK has 'blockbuster potential,' says Clear StreetMoonLake's SLK has 'blockbuster potential,' says Clear Street
Wedbush Analyst forecast on MLTX
Yun Zhong
Wedbush
Wedbush
$34
Buy
78.76%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (NASDAQ: ELDN) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
RBC Capital Analyst forecast on MLTX
Brian Abrahams
RBC Capital
RBC Capital
$13→$16
Hold
-15.88%
Downside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: SI-Bone (NASDAQ: SIBN) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
TD Cowen Analyst forecast on MLTX
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
Goldman Sachs Analyst forecast on MLTX
Richard Law CFA
Goldman Sachs
Goldman Sachs
$11→$12
Sell
-36.91%
Downside
Reiterated
05/11/26
Goldman Sachs Keeps Their Sell Rating on MoonLake Immunotherapeutics (MLTX)
Wolfe Research Analyst forecast on MLTX
Andy Chen
Wolfe Research
Wolfe Research
$12→$24
Buy
26.18%
Upside
Upgraded
03/23/26
MoonLake upgraded to Outperform from Underperform at Wolfe ResearchMoonLake upgraded to Outperform from Underperform at Wolfe Research
Citi Analyst forecast on MLTX
Samantha Semenkow
Citi
Citi
$6
Sell
-68.45%
Downside
Reiterated
03/20/26
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (NASDAQ: MLTX), Solid Biosciences (NASDAQ: SLDB) and Merck & Company (NYSE: MRK)
Rothschild & Co Redburn Analyst forecast on MLTX
Qize Ding
Rothschild & Co Redburn
Rothschild & Co Redburn
$12→$40
Buy
110.30%
Upside
Upgraded
03/19/26
MoonLake upgraded to Buy from Neutral at Rothschild & Co RedburnMoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
Stifel Nicolaus Analyst forecast on MLTX
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$13→$19
Hold
-0.11%
Downside
Reiterated
03/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (NASDAQ: MLTX) and Genfit (Other OTC: GNFTF)
Cantor Fitzgerald Analyst forecast on MLTX
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
12/04/25
FDA moving to one trial for approval could be positve for MoonLake, says CantorFDA moving to one trial for approval could be positve for MoonLake, says Cantor
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MLTX
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$45
Buy
136.59%
Upside
Reiterated
07/20/26
Analyst Maintains Buy on MoonLake, Reiterates $45 Price Target on Strong Financing and Sonelokimab Commercial Potential
Guggenheim Analyst forecast on MLTX
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$40
Buy
110.30%
Upside
Reiterated
06/22/26
Guggenheim Remains a Buy on MoonLake Immunotherapeutics (MLTX)
BTIG Analyst forecast on MLTX
Julian Harrison
BTIG
BTIG
$30
Buy
57.73%
Upside
Reiterated
06/22/26
Buy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained
LifeSci Capital Analyst forecast on MLTX
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$33
Buy
73.50%
Upside
Reiterated
06/22/26
MoonLake Reiterated at Buy as Sonelokimab Data Underscore HS Potential; $33 Price Target Maintained
Needham Analyst forecast on MLTX
Serge Belanger
Needham
Needham
$30
Buy
57.73%
Upside
Reiterated
06/22/26
Buy Rating Reiterated on SLK’s Strong Phase 3 HS Data and BLA Path; $30 Price Target Maintained
Clear Street Analyst forecast on MLTX
Kaveri Pohlman
Clear Street
Clear Street
$70
Buy
268.03%
Upside
Reiterated
06/22/26
MoonLake's SLK has 'blockbuster potential,' says Clear StreetMoonLake's SLK has 'blockbuster potential,' says Clear Street
Wedbush Analyst forecast on MLTX
Yun Zhong
Wedbush
Wedbush
$34
Buy
78.76%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (NASDAQ: ELDN) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
RBC Capital Analyst forecast on MLTX
Brian Abrahams
RBC Capital
RBC Capital
$13→$16
Hold
-15.88%
Downside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: SI-Bone (NASDAQ: SIBN) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
TD Cowen Analyst forecast on MLTX
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/11/26
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
Goldman Sachs Analyst forecast on MLTX
Richard Law CFA
Goldman Sachs
Goldman Sachs
$11→$12
Sell
-36.91%
Downside
Reiterated
05/11/26
Goldman Sachs Keeps Their Sell Rating on MoonLake Immunotherapeutics (MLTX)
Wolfe Research Analyst forecast on MLTX
Andy Chen
Wolfe Research
Wolfe Research
$12→$24
Buy
26.18%
Upside
Upgraded
03/23/26
MoonLake upgraded to Outperform from Underperform at Wolfe ResearchMoonLake upgraded to Outperform from Underperform at Wolfe Research
Citi Analyst forecast on MLTX
Samantha Semenkow
Citi
Citi
$6
Sell
-68.45%
Downside
Reiterated
03/20/26
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (NASDAQ: MLTX), Solid Biosciences (NASDAQ: SLDB) and Merck & Company (NYSE: MRK)
Rothschild & Co Redburn Analyst forecast on MLTX
Qize Ding
Rothschild & Co Redburn
Rothschild & Co Redburn
$12→$40
Buy
110.30%
Upside
Upgraded
03/19/26
MoonLake upgraded to Buy from Neutral at Rothschild & Co RedburnMoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
Stifel Nicolaus Analyst forecast on MLTX
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$13→$19
Hold
-0.11%
Downside
Reiterated
03/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (NASDAQ: MLTX) and Genfit (Other OTC: GNFTF)
Cantor Fitzgerald Analyst forecast on MLTX
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
12/04/25
FDA moving to one trial for approval could be positve for MoonLake, says CantorFDA moving to one trial for approval could be positve for MoonLake, says Cantor
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MoonLake Immunotherapeutics

3 Months
Thomas SmithLeerink Partners
Success Rate
17/26 ratings generated profit
65%
Average Return
+29.54%
Copying Thomas Smith's trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +29.54% per trade.
1 Year
Thomas SmithLeerink Partners
Success Rate
13/26 ratings generated profit
50%
Average Return
+65.60%
Copying Thomas Smith's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +65.60% per trade.
2 Years
Thomas SmithLeerink Partners
Success Rate
9/26 ratings generated profit
35%
Average Return
+43.45%
Copying Thomas Smith's trades and holding each position for 2 Years would result in 34.62% of your transactions generating a profit, with an average return of +43.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MLTX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
17
19
18
17
9
Buy
7
5
5
4
3
Hold
3
3
2
2
0
Sell
1
1
1
1
0
Strong Sell
2
1
0
0
0
total
30
29
26
24
12
In the current month, MLTX has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MLTX average Analyst price target in the past 3 months is 34.44.
Each month's total comprises the sum of three months' worth of ratings.

MLTX Financial Forecast

MLTX Earnings Forecast

Next quarter’s earnings estimate for MLTX is -$0.92 with a range of -$1.02 to -$0.75. The previous quarter’s EPS was -$0.98. MLTX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year MLTX has Outperformed its overall industry.
Next quarter’s earnings estimate for MLTX is -$0.92 with a range of -$1.02 to -$0.75. The previous quarter’s EPS was -$0.98. MLTX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year MLTX has Outperformed its overall industry.
No data currently available

MLTX Sales Forecast

Next quarter’s sales forecast for MLTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MLTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 30.22% of the time in the same period. In the last calendar year MLTX has Performed in-line its overall industry.
Next quarter’s sales forecast for MLTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MLTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 30.22% of the time in the same period. In the last calendar year MLTX has Performed in-line its overall industry.

MLTX Stock Forecast FAQ

What is MLTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Moonlake Immunotherapeutics’s 12-month average price target is 34.44.
    What is MLTX’s upside potential, based on the analysts’ average price target?
    Moonlake Immunotherapeutics has 81.10% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MLTX a Buy, Sell or Hold?
          Moonlake Immunotherapeutics has a consensus rating of Moderate Buy which is based on 8 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Moonlake Immunotherapeutics’s price target?
            The average price target for Moonlake Immunotherapeutics is 34.44. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $70.00 ,the lowest forecast is $12.00. The average price target represents 81.10% Increase from the current price of $19.02.
              What do analysts say about Moonlake Immunotherapeutics?
              Moonlake Immunotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of MLTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.